Cargando…
Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective
BACKGROUND: A number of diabetic patients with diabetic neuropathy, in India, were treated with epalrestat, an aldose reductase inhibitor. In this study, more than 2000 patients with diabetic neuropathy, who were treated with epalrestat for 3-12 months, were analyzed to assess the efficacy and the a...
Autores principales: | Sharma, S. R., Sharma, Nalini |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771994/ https://www.ncbi.nlm.nih.gov/pubmed/19893679 http://dx.doi.org/10.4103/0972-2327.44558 |
Ejemplares similares
-
Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG
por: Iyer, Sangeetha, et al.
Publicado: (2019) -
Amelioration of Bleomycin-induced Pulmonary Fibrosis of Rats by an Aldose Reductase Inhibitor, Epalrestat
por: Li, Xianwei, et al.
Publicado: (2015) -
Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats
por: Yang, Bai-Bing, et al.
Publicado: (2018) -
Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat
por: Hotta, N, et al.
Publicado: (2008) -
Correction: Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats
por: Yang, Bai-Bing, et al.
Publicado: (2019)